{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:52:52Z","timestamp":1762260772963,"version":"build-2065373602"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFB3800900"],"award-info":[{"award-number":["2021YFB3800900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233007"],"award-info":[{"award-number":["52233007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"publisher","award":["YXY2301005"],"award-info":[{"award-number":["YXY2301005"]}],"id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jconrel.2025.113851","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T18:37:08Z","timestamp":1747507028000},"page":"113851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In situ therapeutic vaccines for leukemia by chemo-nanoadjuvant therapy"],"prefix":"10.1016","volume":"383","author":[{"given":"Peng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanhong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruonan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113851_bb0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113851_bb0010","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113851_bb0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113851_bb0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2025.113851_bb0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113851_bb0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113851_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202210452","article-title":"Biomaterial-based in situ cancer vaccines","volume":"36","author":"Bo","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.113851_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202300121","article-title":"Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.113851_bb0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jconrel.2022.05.005","article-title":"Roadmap to next-generation cancer vaccines","volume":"347","author":"Zheng","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113851_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114107","article-title":"Nanovaccines with cell-derived components for cancer immunotherapy","volume":"182","author":"Meng","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113851_bb0055","first-page":"491","article-title":"Engineered tumor cell-derived vaccines against cancer: the art of combating poison with poison","volume":"22","author":"Zhang","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2025.113851_bb0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","article-title":"Enhancing in situ cancer vaccines using delivery technologies","volume":"23","author":"Gong","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113851_bb0065","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz4204","article-title":"Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses","volume":"6","author":"Chao","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.113851_bb0070","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1038\/s41467-024-53084-w","article-title":"Two-dimensional coordination risedronate-manganese nanobelts as adjuvant for cancer radiotherapy and immunotherapy","volume":"15","author":"Huang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113851_bb0075","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1038\/s41467-021-24564-0","article-title":"Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113851_bb0080","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1038\/s41467-023-40996-2","article-title":"A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy","volume":"14","author":"Kang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113851_bb0085","doi-asserted-by":"crossref","first-page":"8187","DOI":"10.1038\/s41467-024-52458-4","article-title":"Strategically engineered Au(I) complexes for orchestrated tumor eradication via chemo-phototherapy and induced immunogenic cell death","volume":"15","author":"Feng","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113851_bb0090","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41467-021-21047-0","article-title":"Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer","volume":"12","author":"Jiang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113851_bb0095","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1038\/s41467-022-33831-7","article-title":"In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses","volume":"13","author":"Guo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113851_bb0100","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41419-021-04178-6","article-title":"Immunogenic cell death and immunogenic surrender: related but distinct mechanisms of immune surveillance","volume":"12","author":"Mezzapelle","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2025.113851_bb0105","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113851_bb0110","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.accounts.3c00771","article-title":"Nanomedicines for an enhanced immunogenic cell death-based in situ Cancer vaccination response","volume":"57","author":"Zhao","year":"2024","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2025.113851_bb0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.113851_bb0120","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113851_bb0125","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41568-021-00355-z","article-title":"Leukaemia: a model metastatic disease","volume":"21","author":"Whiteley","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"2019","key":"10.1016\/j.jconrel.2025.113851_bb0130","first-page":"363","article-title":"Cancer treatment and survivorship statistics","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2025.113851_bb0135","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.113851_bb0140","article-title":"Systemic multifunctional Nanovaccines for potent personalized immunotherapy of acute myeloid leukemia","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.113851_bb0145","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.2018.208835","article-title":"Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1\/TET1\/5hmC","volume":"105","author":"Li","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2025.113851_bb0150","doi-asserted-by":"crossref","DOI":"10.1177\/09636897231183559","article-title":"Homoharringtonine-based induction therapy reduces the recurrence rate of pediatric acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Wang","year":"2023","journal-title":"Cell Transplant."},{"key":"10.1016\/j.jconrel.2025.113851_bb0155","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cncr.24601","article-title":"Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2025.113851_bb0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-7-2","article-title":"Homoharringtonine and omacetaxine for myeloid hematological malignancies","volume":"7","author":"L\u00fc","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.113851_bb0165","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2019.234880","article-title":"A new kid on the block for acute myeloid leukemia treatment? Homoharringtonine interferes with key pathways in acute myeloid leukemia cells","volume":"105","author":"Bohlander","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2025.113851_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf3735","article-title":"Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia","volume":"8","author":"Lam","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.113851_bb0175","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1073\/pnas.1818539116","article-title":"Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-\u03baB repressing factor","volume":"116","author":"Chen","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.113851_bb0180","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.2021013156","article-title":"Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2","volume":"139","author":"Mill","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113851_bb0185","doi-asserted-by":"crossref","DOI":"10.1021\/acsami.4c13041","article-title":"Muramyl dipeptide-presenting Polymersomes as artificial Nanobacteria to boost systemic antitumor immunity","volume":"16","author":"Cui","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2025.113851_bb0190","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1021\/acs.nanolett.1c00977","article-title":"Cooperative self-assembled nanoparticle induces sequential immunogenic cell death and toll-like receptor activation for synergistic chemo-immunotherapy","volume":"21","author":"Wang","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2025.113851_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc3013","article-title":"Cryo-shocked cancer cells for targeted drug delivery and vaccination","volume":"6","author":"Ci","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2025.113851_bb0200","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.it.2015.12.003","article-title":"Integration of innate immune signaling","volume":"37","author":"Thaiss","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2025.113851_bb0205","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2025.113851_bb0210","doi-asserted-by":"crossref","first-page":"490","DOI":"10.21037\/atm-22-1459","article-title":"Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms","volume":"10","author":"Yuan","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.113851_bb0215","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood-2016-08-734798","article-title":"Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment","volume":"129","author":"Shafat","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113851_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8828","article-title":"Overcoming adaptive therapy resistance in AML by targeting immune response pathways","volume":"11","author":"Melgar","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.113851_bb0225","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2025.113851_bb0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2019.10.032","article-title":"Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model","volume":"469","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.113851_bb0235","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nri1329","article-title":"Immunotherapeutic uses of CpG oligodeoxynucleotides","volume":"4","author":"Klinman","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2025.113851_bb0240","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.actbio.2022.11.007","article-title":"Amplifying STING activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia","volume":"157","author":"Wang","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2025.113851_bb0245","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41375-021-01432-w","article-title":"Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy","volume":"36","author":"Johnson","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.113851_bb0250","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/annonc\/mdx179","article-title":"Pattern recognition receptors: immune targets to enhance cancer immunotherapy","volume":"28","author":"Shekarian","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2025.113851_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303690","article-title":"Uplifting antitumor immunotherapy with lymph-node-targeted and ratio-controlled Codelivery of tumor cell lysate and adjuvant","volume":"13","author":"Cui","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2025.113851_bb0260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41551-019-0503-3","article-title":"A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia","volume":"4","author":"Shah","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2025.113851_bb0265","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/sj.leu.2404287","article-title":"Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia","volume":"20","author":"Jin","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2025.113851_bb0270","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/blood-2024-203359","article-title":"Azacitidine, Homoharringtonine and Cytarabine combined with granulocyte Colony-stimulating factor as frontline treatment for older patients with acute myeloid leukemia: a prospective, multicenter, single-arm phase III study in China","volume":"144","author":"Ma","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113851_bb0275","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jconrel.2020.09.031","article-title":"Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia","volume":"327","author":"Yan","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113851_bb0280","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(13)70152-9","article-title":"Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial","volume":"14","author":"Jin","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.113851_bb0285","first-page":"1675","article-title":"Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia","volume":"4","author":"Knorr","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2025.113851_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","author":"Bhagwat","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113851_bb0295","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12951-022-01491-w","article-title":"Biomimetic doxorubicin\/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia","volume":"20","author":"Chen","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2025.113851_bb0300","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s41416-020-0955-y","article-title":"An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia","volume":"123","author":"Shin","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.113851_bb0305","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41551-020-00624-6","article-title":"Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen","volume":"5","author":"Xie","year":"2021","journal-title":"Nat. Biomed. Eng."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:24:13Z","timestamp":1762259053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925004717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":61,"alternative-id":["S0168365925004717"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113851","relation":{},"ISSN":["0168-3659"],"issn-type":[{"type":"print","value":"0168-3659"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In situ therapeutic vaccines for leukemia by chemo-nanoadjuvant therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113851"}}